TARS · Insider trading · 13F holders · Congress trades
Tarsus Pharmaceuticals, Inc. (TARS)
Who is buying and selling TARS: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 17
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $5.2M
- Congress trades, 12 months
- 0
TARS at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 4 TARS insiders filed 6 sales worth $5.2M on SEC Form 4, and no open-market purchases; 6 of the sales were pre-planned under Rule 10b5-1.
- 17 13F filers hold TARS among their 50 largest positions, worth $922.0M combined. The biggest bets by portfolio weight are Tang Capital Management LLC (4.5%), Deep Track Capital, LP (3.4%) and Paradigm Biocapital Advisors LP (3.3%). In their latest 13Fs, 0 managers opened a new position and 7 added to one.
- No member of Congress has disclosed a trade in TARS.
- TARS last closed at $74.20 on Oct 29, 2026.
TARS insider trading
Between Aug 1, 2026 and Oct 29, 2026, 4 TARS insiders filed 6 sales worth $5.2M on SEC Form 4, and no open-market purchases; 6 of the sales were pre-planned under Rule 10b5-1.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Link William J Phd | Director | Sale10b5-1 | 12,500 | $78.38 | $980K | SEC |
| Sep 9, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Sale10b5-1 | 13,953 | $87.50 | $1.2M | SEC |
| Sep 9, 2026 | Azamian Bobak R. | President/CEO and Board Chair, Director | Sale10b5-1 | 10,000 | $90.56 | $906K | SEC |
| Sep 9, 2026 | Neervannan Seshadri | Chief Operating Officer | Sale10b5-1 | 4,564 | $85.00 | $388K | SEC |
| Sep 3, 2026 | Lin Elizabeth Yeu | Chief Medical Officer | Sale10b5-1 | 11,578 | $77.56 | $898K | SEC |
| Sep 3, 2026 | Azamian Bobak R. | President/CEO and Board Chair, Director | Sale10b5-1 | 10,000 | $80.06 | $801K | SEC |
Who owns TARS? Hedge funds and superinvestors
17 13F filers hold TARS among their 50 largest positions, worth $922.0M combined. The biggest bets by portfolio weight are Tang Capital Management LLC (4.5%), Deep Track Capital, LP (3.4%) and Paradigm Biocapital Advisors LP (3.3%). In their latest 13Fs, 0 managers opened a new position and 7 added to one.
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Deep Track Capital, LPHedge fund | 3.4% | $230.8M | 3,666,768 | +1.9% shares | Q2 2026 |
| Rtw Investments, LPHedge fund | 1.8% | $211.3M | 3,357,059 | +0.3% shares | Q2 2026 |
| Paradigm Biocapital Advisors LPHedge fund | 3.3% | $174.7M | 2,775,649 | +8.3% shares | Q2 2026 |
| Tang Capital Management LLCHedge fund | 4.5% | $98.7M | 1,568,266 | +31.9% shares | Q2 2026 |
| Vestal Point Capital, LPHedge fund | 1.5% | $66.1M | 1,050,000 | — | Q2 2026 |
| Frazier Life Sciences Management, L.P.Hedge fund | 1.0% | $45.9M | 728,644 | +0.0% shares | Q2 2026 |
| Tri Locum Partners LPHedge fund | 2.5% | $20.7M | 328,340 | +30.0% shares | Q2 2026 |
| Mpm Bioimpact LLCHedge fund | 1.2% | $20.3M | 322,007 | -2.3% shares | Q2 2026 |
| Rock Springs Capital Management LPHedge fund | 0.9% | $17.4M | 277,087 | +23.1% shares | Q2 2026 |
| Parkman Healthcare Partners LLCHedge fund | 1.0% | $9.4M | 150,000 | — | Q2 2026 |
| Seven Fleet Capital Management LPHedge fund | 1.3% | $7.9M | 117,067 | — | Q2 2026 |
| Cormorant Asset Management, LPHedge fund | 0.3% | $6.3M | 100,000 | -55.6% shares | Q2 2026 |
| HighVista Strategies LLCHedge fund | 1.2% | $5.5M | 87,060 | +65.9% shares | Q2 2026 |
| Sands Capital Alternatives, LLCHedge fund | 0.9% | $5.3M | 85,000 | +0.0% shares | Q2 2026 |
| Sectoral Asset Management IncHedge fund | 0.6% | $836K | 13,285 | +17.9% shares | Q2 2026 |
| Pale Fire Capital SEAsset manager | 0.0% | $617K | 9,802 | +73.4% shares | Q2 2026 |
| PSP Research LLCInstitutional asset manager | 0.2% | $275K | 3,500 | -50.0% shares | Q3 2026 |
Each manager counts with its latest 13F (Q3 2026: 1, Q2 2026: 16). Screen TARS in the grand portfolio →
TARS stock trades by members of Congress
No member of Congress has disclosed a trade in TARS.
TARS questions and answers
Are insiders buying TARS stock?
Between Aug 1, 2026 and Oct 29, 2026, 4 TARS insiders filed 6 sales worth $5.2M on SEC Form 4, and no open-market purchases; 6 of the sales were pre-planned under Rule 10b5-1.
Which hedge funds own TARS?
17 13F filers hold TARS among their 50 largest positions, worth $922.0M combined. The biggest bets by portfolio weight are Tang Capital Management LLC (4.5%), Deep Track Capital, LP (3.4%) and Paradigm Biocapital Advisors LP (3.3%). In their latest 13Fs, 0 managers opened a new position and 7 added to one.
Has Congress traded TARS?
No member of Congress has disclosed a trade in TARS.
Who is the largest holder of TARS?
Among 13F filers, Deep Track Capital, LP reports the largest TARS position, $230.8M (3,666,768 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Tang Capital Management LLC's: 4.5% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.